Document is current
Any future updates will be listed below
-
Authors
Naidoo, Kimesh Loganathan https://orcid.org/0000-0003-4940-0534
Dladla, Sindisiwa https://orcid.org/0009-0005-4590-9714
Mphahlele, Reratilwe Ephenia
Mosler, Gioia
Muyemayema, Sophie
Ssemata, Andrew Sentoogo https://orcid.org/0000-0003-0060-0842
Mkutumula, Elizabeth
Adeyeye, Olayinka Olufunke https://orcid.org/0000-0002-1830-0146
Goodman, Olayinka
Kuyinu, Yetunde
Nantanda, Rebecca https://orcid.org/0000-0002-5039-8489
Addo-Yobo, Emmanuel
Owusu, Sandra Kwarteng
Arhin, Bernhard
Ticklay, Ismail
Mujuru, Hilda Angela
Grigg, Jonathan
Masekela, Refiloe https://orcid.org/0000-0001-9665-2035
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (269211)
DH | NIHR | Health Services Research Programme (269211, 269211, 269211, 269211, 26911, 269211, 269211, 269211, 269211)
- License Information
-
More Information
Article History
Received: 11 April 2023
Accepted: 14 September 2023
First Online: 23 September 2023
Competing interests
: The author(s) declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article. The funder did not influence the results and compiling of the manuscript. J.G. reports personal fees from GSK, personal fees from Vifor Pharmaceuticals, personal fees from Novartis, personal fees from BV Pharma, and personal fees from AstraZeneca outside the submitted work. R.M. reports consultancy and advisory board membership from AstraZeneca, Boehringer, and Organon.
